Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 1/20 | 0.49 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.49 |
| ▸ | MCTS1 | Q9ULC4 | 1/20 | 0.49 |
| ▸ | NR1H2 | P55055 | 16/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 13/20 | 0.48 |
| ▸ | RXRA | P19793 | 12/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3472331 | 0.93 | SLC16A3 (0.50) | SLC16A3SLC16A1MCTS1NR1H2NR1H3 | |
| SCHEMBL3471603 | 0.90 | SLC16A3 (0.54) | SLC16A3SLC16A1MCTS1NR1H2NR1H3 | |
| SCHEMBL3472454 | 0.86 | NR1H2 (0.46) | SLC16A3SLC16A1MCTS1NR1H2NR1H3 | |
| SCHEMBL12979324 | 0.86 | NR1H2 (0.47) | SLC16A3SLC16A1MCTS1NR1H2NR1H3 | |
| SCHEMBL16328897 | 0.85 | SLC16A3 (0.49) | SLC16A3SLC16A1MCTS1NR1H2NR1H3 | |
| SCHEMBL12979599 | 0.84 | NR1H2 (0.49) | SLC16A3SLC16A1MCTS1NR1H2NR1H3 | |
| SCHEMBL2256629 | 0.82 | NR1H2 (0.57) | SLC16A3SLC16A1MCTS1NR1H2NR1H3 | |
| SCHEMBL3472092 | 0.80 | NR1H2 (0.70) | SLC16A3SLC16A1MCTS1NR1H2NR1H3 | |
| SCHEMBL3471700 | 0.78 | NR1H2 (0.59) | SLC16A3SLC16A1MCTS1NR1H2NR1H3 | |
| SCHEMBL2258761 | 0.77 | NR1H2 (0.56) | SLC16A3SLC16A1MCTS1NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703805-B2 | Modulators of LXR | EXELIXIS PATENT COMPANY LLC (US) | 2014-04-22 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100331295-A1 | MODULATORS OF LXR | EXELIXIS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| EP-1910307-A1 | PYRAZOLE BASED LXR MODULATORS | Exelixis, Inc. (US) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002559-A1 | PYRAZOLE BASED LXR MODULATORS | EXELIXIS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331295-A1 | MODULATORS OF LXR | NR1H2, NR1H3, NR1H4 | SLC16A3 1730/4885SLC16A1 1358/4885MCTS1 4472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.